ondasdechoque.org
PT-BR

Calcific shoulder tendinitis: clinical, ultrasound and blood-marker changes after one shockwave session · Lab and clinical study · 2024

What changed after one shockwave session for calcium deposits in the shoulder?

In this study, shoulder pain fell from about 5 to about 2 out of 10 in the year after one focused shockwave session, function scores rose, and the deposits shrank on X-ray. There was no untreated group, and these deposits can also shrink on their own.

Improved over time
adults with calcium deposits in one shoulder
28
focused session, without numbing
1
followed up
12 mo

Good to know: Blood markers were also measured.

Chou WY, Wu KT, Chen PC, et al. International Journal of Surgery (London, England), 2024 · Read the paper ↗

What happened

Shoulder pain

0–10 pain scale · start and 12 months after one session

StartAfter 12 months

Average pain went from about 5 to about 2 out of 10 in the year after one session.
Show the numbers
GroupPeopleStartAfter 12 months
One focused shockwave session285.352.21

The treatment

One focused shockwave session

Focused, 1 session

Focused wavesMeet at a focal zone below the skin
Sessions
1
Pulses
3,000 per session
Strength
0.32mJ/mm² device intensity level 7 · 4 per second
Numbing
None
Device
Orthospec (Medispec Ltd.)

Compared with: No comparison group; deposits that looked dense or faint on X-ray were compared with each other

Settings are what each study used, not a prescription.

This protocol among the library’s

Each dot is a group treated with shockwaves in a study in this library, at the midpoint when the paper gave a range. The dark dots are this study.

Energy, focused waves0.32 mJ/mm²

Of the other 29 groups: 22 lower, 3 the same, 4 higher.

Pulses per session3,000

Of the other 69 groups: 48 lower, 8 the same, 13 higher.

Sessions1

Of the other 78 groups: 13 the same, 65 higher.

Who took part

28 adults (22 women, 6 men; average age about 59) with calcium deposits in one shoulder tendon for 6 to 30 months, after at least 3 months of other care that had not helped.

One focused shockwave session28 people

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

28 adults (6 men, 22 women; mean age 59.4 years, range 40–82) with calcific tendinitis of one shoulder and symptoms for 6–30 months (mean 12.3) after at least 3 months of physiotherapy, NSAIDs or analgesics without response, recruited by one physician at Kaohsiung Chang Gung Memorial Hospital, Taiwan, from August 2018 to July 2019. Fifteen had radiodense and 13 radiolucent deposits; all 28 completed 12 months of follow-up.

All treated patients (one focused session)28enrolled

Single treated cohort; no randomisation and no untreated control. Participants, one shoulder each (28 patients/28 shoulders). Subgroups by deposit type (15 radiodense, 13 radiolucent) are observational strata. All 28 completed every follow-up.

Pain intensity1 reported outcome
01
12 months after one session

Pain intensity

Visual analogue scale (VAS), reported as intensity of pain Points (range not stated)

means
GroupnBaselineFollow-up
All treated patients (one focused session)285.35 (SD 1.22) (range 1–8)2.21 (SD 1.45) (range 0–5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp >0.05

Radiodense versus radiolucent deposits at each visit (observational subgroups, same treatment)

Mean pain in the whole cohort was 5.35 at baseline, 4.36 at 1 month, 3.21 at 3 months, 2.89 at 6 months and 2.21 at 12 months, each marked significant against baseline. Radiodense and radiolucent groups did not differ at any visit (12 months: 2.3 versus 2.1).

Analysis details and source

Means ± SD (range) for the whole cohort from Table 2. Change is measured against baseline in one treated group; there is no untreated control, so it is not a treatment effect. In Table 2 the radiolucent group's pain values (4.5, 3.2, 3.0 and 2.1) carry no significance marker at any visit, although the text says both groups improved in all parameters.

Constant-Murley score1 reported outcome
02
12 months after one session

Constant-Murley score

Constant-Murley (CM) score Points (range not stated in the paper)

means
GroupnBaselineFollow-up
All treated patients (one focused session)2848.43 (SD 10.11) (range 31–73)70.39 (SD 12.25) (range 43–93)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp >0.05

Radiodense versus radiolucent deposits at each visit (observational subgroups, same treatment)

The whole-cohort mean rose from 48.43 at baseline to 54.64 at 1 month, 61.21 at 3 months, 64.39 at 6 months and 70.39 at 12 months, each marked significant against baseline. Subgroups did not differ (12 months: radiodense 69.6, radiolucent 71.3).

Analysis details and source

Means ± SD (range) for the whole cohort from Table 2. Change is measured against baseline in one treated group; there is no untreated control, so it is not a treatment effect. Higher scores indicate better shoulder function on this instrument, but the paper does not state the scale.

ASES shoulder score1 reported outcome
03
12 months after one session

ASES shoulder score

American Shoulder and Elbow Surgeons (ASES) score Points (range not stated in the paper)

means
GroupnBaselineFollow-up
All treated patients (one focused session)2865.71 (SD 9.94) (range 46–93)80.36 (SD 10.01) (range 61–95)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp >0.05

Radiodense versus radiolucent deposits at each visit (observational subgroups, same treatment)

The whole-cohort mean rose from 65.71 at baseline to 68.32 at 1 month, 72.29 at 3 months, 75.64 at 6 months and 80.36 at 12 months, each marked significant against baseline. Subgroups did not differ (12 months: radiodense 80.3, radiolucent 80.5).

Analysis details and source

Means ± SD (range) for the whole cohort from Table 2. Change is measured against baseline in one treated group; there is no untreated control, so it is not a treatment effect.

Calcified size on anteroposterior radiograph1 reported outcome
04
12 months after one session

Deposit size on radiographs

Calcified size on anteroposterior radiograph Millimetres

means
GroupnBaselineFollow-up
All treated patients (one focused session)289.44 (SD 4.82) (range 2.9–22.6)2.9 (SD 4.28) (range 0–16.1)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp >0.05

Radiodense versus radiolucent deposits at each visit (observational subgroups, same treatment)

Whole-cohort mean size was 9.44 mm at baseline, 7.05 at 1 month, 4.53 at 3 months, 4.04 at 6 months and 2.90 mm at 12 months, each marked significant against baseline. Radiodense deposits went from 9.3 to 4.3 mm and radiolucent from 9.5 to 1.3 mm; the subgroup difference in size was not significant at any visit.

Analysis details and source

Means ± SD (range) for the whole cohort from Table 2. Change is measured against baseline in one treated group; there is no untreated control, so it is not a treatment effect. The radiodense 3-month mean (8.4 mm, marked significant) equals its unmarked 1-month value and is hard to reconcile with the whole-cohort 3-month mean of 4.53 mm next to a radiolucent mean of 3.4 mm; this cell may contain an error.

Calcification size reduction (%) from baseline to 12 months1 reported outcome
05
12 months after one session

Percentage reduction in deposit size

Calcification size reduction (%) from baseline to 12 months Percent

means
GroupnBaselineFollow-up
All treated patients (one focused session)28—67.52 (SD 41.18) (range 0–100)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp <0.001

Radiodense versus radiolucent deposits at 12 months (observational subgroups, same treatment)

Mean reduction was 67.52% in the whole cohort, 54.7% (SD 45.3) with radiodense and 82.3% (SD 31.2) with radiolucent deposits, a subgroup difference reported as P<0.001. Ranges ran from 0% to 100%, so some deposits did not shrink at all.

Analysis details and source

Percentages as reported by the authors in Table 2; deposit type is an observed characteristic, not an allocated treatment.

Complete calcification resorption (Table 1)1 reported outcome
06
Final follow-up (12 months)

Complete radiographic resorption

Complete calcification resorption (Table 1) Patients

All treated patients (one focused session)16 / 28

Observed subgroup counts; these are not randomized treatment arms.

Radiodense deposits (Gärtner type I)6 / 15
Radiolucent deposits (Gärtner type II/III)10 / 13
REPORTED COMPARISON TESTp = 0.045

Radiodense versus radiolucent deposits (observational subgroups, same treatment)

On radiographs, 16 of 28 deposits (57%) resorbed completely: 6 of 15 radiodense (40%) and 10 of 13 radiolucent (77%) in Table 1. On ultrasound, by contrast, no deposit had disappeared completely in any patient.

Analysis details and source

Table 1 gives 10/13 (77%) for radiolucent deposits and P<0.05; the Results text gives 40%:70% with P=0.045. The discrepancy is unresolved. Subgroups are observational, not allocated.

Calcified size on ultrasound (Table 3)1 reported outcome
07
12 months after one session

Deposit size on ultrasound

Calcified size on ultrasound (Table 3) As reported in Table 3 (unit not stated)

means
GroupnBaselineFollow-up
All treated patients (one focused session)2812.37 (SD 4.36) (range 5.6–20.4)8.01 (SD 3.61) (range 3.1–16.7)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp >0.05

Radiodense versus radiolucent deposits at each visit (observational subgroups, same treatment)

Whole-cohort mean was 12.37 at baseline, 11.45 at 1 month (not significant), 10.58 at 3 months, 9.19 at 6 months and 8.01 at 12 months, significant from 3 months (overall P<0.001). The radiolucent group changed significantly over time (P<0.001); the radiodense group did not (P>0.05). No patient had complete sonographic resorption.

Analysis details and source

Means ± SD (range) from Table 3; within-group change without a control. Ultrasound sizes are larger than radiographic sizes, as the authors note. The radiodense ranges at 6 and 12 months start at 0, which is hard to reconcile with the statement that no deposit disappeared on ultrasound.

Compressive ultrasound elastography, mean hue value within the deposit1 reported outcome
08
12 months after one session

Tendon stiffness on elastography

Compressive ultrasound elastography, mean hue value within the deposit Hue value, 0 (hardest) to 255 (softest)

means
GroupnBaselineFollow-up
All treated patients (one focused session)2834.19 (SD 17.48) (range 18.44–85.81)37.95 (SD 13.2) (range 13.09–65.77)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp >0.05

Radiodense versus radiolucent deposits at each visit (observational subgroups, same treatment)

Stiffness did not change significantly over 12 months in the whole cohort or in either subgroup (overall P>0.05), and subgroups did not differ.

Analysis details and source

Means ± SD (range) from Table 3. The paper defines the 0–255 hue range but does not say which direction is clinically better, so no scale direction is recorded.

Blood flow around the tendon (power Doppler)1 reported outcome
09
Baseline and 1, 3, 6 and 12 months

Blood flow around the tendon (power Doppler)

Blood flow around the tendon (power Doppler) Patients by Doppler perfusion grade

In the whole cohort, no perfusion signal was seen in 20/28 (71%) at baseline, 10/28 (36%) at 1 month, 9/28 (32%) at 3 months, 15/28 (54%) at 6 months and 17/28 (60%) at 12 months. The authors report improved perfusion at 1 and 3 months that faded by 6 months and read it as part of the mechanism. In Table 3, however, a significant change from baseline is marked only for the radiodense group at 1 month and the radiolucent group at 3 months; the overall test across time is P>0.05 for the whole cohort and both subgroups, and subgroups did not differ.

Analysis details and source

Counts and percentages from Table 3, graded as no, mild or moderate perfusion; Methods describe a 1–4 grading. Within-group observations without a control; no effect estimate.

Serum inflammatory and growth-factor markers1 reported outcome
10
Baseline, 1 week (figure only) and 1, 3, 6 and 12 months

Serum inflammatory and growth-factor markers

Serum inflammatory and growth-factor markers Serum concentration (values in Figure 3 only)

Serum IL-1β and IL-33 did not change significantly over 12 months. IGF-1 was significantly above baseline at 1, 3 and 12 months (the abstract mentions 1 and 3 months only), VEGF at 6 months, and BMP7 rose at 3 months and then fell significantly below baseline at 6 and 12 months. Radiodense and radiolucent groups did not differ at any time. The authors read these patterns as signs that new blood-vessel formation and BMP7 drive early resorption and that later effects relate to blood-vessel formation.

Analysis details and source

Values appear only in Figure 3 and in Supplemental Table 1, which was not available, so no numbers were extracted. Figure 3 also shows a 1-week sample not described in Methods, and its axis units (mg/mL for IL-1β, IL-33, VEGF and BMP7) look implausibly large for serum proteins and may be mislabelled (extractor interpretation). Methods state that marker changes were correlated with clinical and imaging findings, but no correlation results are reported, so the proposed link between markers and resorption was not tested.

How treatment was delivered
Device and modality

Focused shockwave device, Orthospec (Medispec Ltd.).

Energy, pulses and frequency

Intensity level 7, reported as 0.32 mJ/mm²; 3,000 impulses at 4 Hz.

Sessions

One session. The authors suggest a second session at 3 months but did not test it.

Target, guidance and anaesthesia

Applied under image guidance directly to the tendon area with the calcific deposit (supraspinatus in most patients); the imaging method for guidance is not stated. No anaesthesia or analgesics.

Co-interventions and comparator

Co-interventions not reported. No sham, untreated or active comparator; radiodense and radiolucent deposits are compared as observed subgroups.

Assessments

VAS, Constant-Murley and ASES scores; anteroposterior and scapular-Y radiographs (Gärtner–Heyer type, size in mm); ultrasound with a Siemens Acuson S2000 4–9 MHz linear probe (power Doppler perfusion, compressive elastography); serum IL-1β, IL-33, VEGF, IGF-1 and BMP7 by R&D Systems ELISA kits; before treatment and at 1, 3, 6 and 12 months.

HARMS & TOLERABILITY

Adverse events are not reported: the paper gives no information on treatment pain, bruising or other side effects, so their frequency is unknown. No anaesthesia was used. Funding came from the Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital and Taiwan's National Science and Technology Council (MOST 107-2314-B-182A-032). The authors declare no honoraria, consulting fees or commercial benefits, and no ties to the device maker are reported. They work at the hospital's Center for Shockwave Medicine and Tissue Engineering, and the paper was invited for a journal special issue on shockwave treatment.

LIMITS OF THE ANALYSIS

Author-reported: a limited panel of molecular markers and only one session although two or three are common in practice.

Extractor assessment: there is no untreated or sham group, and calcific tendinitis can resolve on its own, so the improvements and resorption cannot be separated from natural history; the "case–control" label does not match the design.

Extractor assessment: internal inconsistencies, including 77% (Table 1) versus 70% (text) complete resorption in radiolucent deposits, perfusion gains claimed for the whole cohort but not marked significant in Table 3, unmarked pain changes in the radiolucent group in Table 2, an implausible radiodense 3-month size value, ultrasound ranges reaching 0 despite no complete sonographic resorption, and IGF-1 time points that differ between abstract and results.

Extractor assessment: the statistical description is confused (a Mann–Whitney test is named for normally distributed data, and normality is said to be tested by ANOVA); many time points and markers were tested without adjustment for multiple comparisons; the power calculation does not name its outcome.

Extractor assessment: the conclusion that shockwaves enhance perfusion through IGF-1, VEGF and BMP7 and so drive resorption goes beyond the data, since no correlation or mediation analysis is reported and the marker values are shown only in a figure; the advice to give a second session at 3 months was not tested. The reference given for the prognostic value of Gärtner type I deposits (reference 7) is a paper on spinal-cord ischaemia in aortic surgery.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: a limited panel of molecular markers and only one session although two or three are common in practice.
  • Extractor assessment: there is no untreated or sham group, and calcific tendinitis can resolve on its own, so the improvements and resorption cannot be separated from natural history; the "case–control" label does not match the design.
  • Extractor assessment: internal inconsistencies, including 77% (Table 1) versus 70% (text) complete resorption in radiolucent deposits, perfusion gains claimed for the whole cohort but not marked significant in Table 3, unmarked pain changes in the radiolucent group in Table 2, an implausible radiodense 3-month size value, ultrasound ranges reaching 0 despite no complete sonographic resorption, and IGF-1 time points that differ between abstract and results.
  • Extractor assessment: the statistical description is confused (a Mann–Whitney test is named for normally distributed data, and normality is said to be tested by ANOVA); many time points and markers were tested without adjustment for multiple comparisons; the power calculation does not name its outcome.
  • Extractor assessment: the conclusion that shockwaves enhance perfusion through IGF-1, VEGF and BMP7 and so drive resorption goes beyond the data, since no correlation or mediation analysis is reported and the marker values are shown only in a figure; the advice to give a second session at 3 months was not tested. The reference given for the prognostic value of Gärtner type I deposits (reference 7) is a paper on spinal-cord ischaemia in aortic surgery.
Research review

Source-linked critical reading

Single-centre prospective cohort in which all 28 patients received one session of focused shockwave therapy, with serum biomarker measurements. The authors call it a case–control study, but there is no untreated or sham group: the two groups compared are radiodense (Gärtner type I) and radiolucent (type II/III) deposits, all treated the same way.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Single-centre prospective cohort in which all 28 patients received one session of focused shockwave therapy, with serum biomarker measurements. The authors call it a case–control study, but there is no untreated or sham group: the two groups compared are radiodense (Gärtner type I) and radiolucent (type II/III) deposits, all treated the same way.

Participants and setting

28 adults (6 men, 22 women; mean age 59.4 years, range 40–82) with calcific tendinitis of one shoulder and symptoms for 6–30 months (mean 12.3) after at least 3 months of physiotherapy, NSAIDs or analgesics without response, recruited by one physician at Kaohsiung Chang Gung Memorial Hospital, Taiwan, from August 2018 to July 2019. Fifteen had radiodense and 13 radiolucent deposits; all 28 completed 12 months of follow-up.

Treatment protocol

One session of focused shockwaves (Orthospec, Medispec Ltd.) at intensity level 7, reported as 0.32 mJ/mm², 3,000 impulses at 4 Hz, applied under image guidance directly to the calcific deposit without anaesthesia or analgesics, following the group's earlier protocol. No co-interventions are reported. The authors suggest a second session at 3 months, but this was not tested.

Comparison

No untreated, sham or alternative-treatment group. Changes are compared with each patient's own baseline, and radiodense deposits are compared with radiolucent deposits. Because calcific tendinitis can resolve on its own, as the authors acknowledge, improvement over time cannot be attributed to the treatment alone.

What was measured

Pain (VAS), Constant-Murley and ASES scores; deposit type and size on radiographs, with complete resorption and percentage size reduction; deposit size, tendon stiffness (elastography) and power Doppler perfusion on ultrasound; and serum IL-1β, IL-33, IGF-1, VEGF and BMP7. All were measured before treatment and at 1, 3, 6 and 12 months.

Results and interpretation

Over 12 months, mean pain fell from 5.35 to 2.21, and Constant-Murley and ASES scores rose (48.43 to 70.39; 65.71 to 80.36), with no significant differences between deposit types. On radiographs, mean deposit size fell from 9.44 to 2.90 mm; complete radiographic resorption was more frequent with radiolucent deposits (Table 1: 10/13 versus 6/15; the text gives 70% versus 40%, P=0.045). On ultrasound, deposits shrank from 3 months on, but none disappeared completely. The authors report more Doppler perfusion at 1–3 months, fading by 6 months; tendon stiffness did not change. Serum IL-1β and IL-33 did not change; IGF-1 rose at 1, 3 and 12 months, VEGF at 6 months, and BMP7 rose at 3 months and then fell below baseline at 6 and 12 months. All of these are changes within one treated group; the only comparison is between deposit types.

Harms and disclosures

Adverse events are not reported: the paper gives no information on treatment pain, bruising or other side effects, so their frequency is unknown. No anaesthesia was used. Funding came from the Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital and Taiwan's National Science and Technology Council (MOST 107-2314-B-182A-032). The authors declare no honoraria, consulting fees or commercial benefits, and no ties to the device maker are reported. They work at the hospital's Center for Shockwave Medicine and Tissue Engineering, and the paper was invited for a journal special issue on shockwave treatment.

Limitations

No untreated or sham group, in a condition that can resolve on its own; 28 patients at one centre; one session only; adverse events not reported; conflicting numbers between text and tables (complete resorption 77% vs 70%; perfusion significance; pain markers in the radiolucent group; ultrasound ranges reaching 0); confused statistical description and no adjustment for many tests; biomarker values shown only in a figure with doubtful units, and no correlation analysis linking markers to clinical or imaging change. The authors themselves note the single session and limited marker panel.

Applicability

Applies to adults with symptomatic calcific shoulder tendinitis after failed conservative care, treated with one high-energy focused session on this device. It describes what changes after treatment and offers hypotheses about mechanism; it cannot estimate the treatment effect, show that blood markers explain resorption, or support a fixed retreatment schedule.

What stronger evidence needs

A randomised trial against sham or another active treatment, with blinded imaging assessment, prespecified biomarker analyses linked to clinical and imaging change, reporting of adverse events, and a tested comparison of one versus two sessions.

THE ORIGINAL SOURCE

Read the original article.

Clinical, sonographic, and molecular changes in calcific tendinitis of the shoulder following extracorporeal shockwave therapy: a prospective case-control study.

Chou WY, Wu KT, Chen PC, Jhan SW, Wu CF, Cheng JH. · International journal of surgery (London, England) · 2024

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →